NCT04931992 (MOLAM) is a clinical trial of No intervention in Acute Myeloid Leukemia, sponsored by University Hospital, Angers.

Who is sponsoring NCT04931992?

NCT04931992 is sponsored by University Hospital, Angers.

What drugs are being tested in NCT04931992?

Interventions in NCT04931992: No intervention.

What condition does NCT04931992 study?

NCT04931992 studies Acute Myeloid Leukemia.

Is NCT04931992 still recruiting?

NCT04931992 is currently status unknown. Last updated 18 June 2021.

Last reviewed 2021-06-18 · How we verify

NCT04931992: MOLAM

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Outcome of Patients With CBF and/or NPM1-mutated AML in First Molecular Relapse.

Status unknown Last updated 18 June 2021

What this trial tests

trial testing No intervention in Acute Myeloid Leukemia in 100 participants. Status unknown.

Timeline

1 June 2021

Primary endpoint
31 December 2021

31 December 2021

Quick facts

Lead sponsor	University Hospital, Angers
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	100
Start date	1 June 2021
Primary completion	31 December 2021
Estimated completion	31 December 2021
Sites	1 location across France

Drugs / interventions tested

No intervention

Conditions studied

Acute Myeloid Leukemia — all drugs for Acute Myeloid Leukemia →

Sponsor

University Hospital, Angers

Who can join

Adults 18 to 61, any sex, with Acute Myeloid Leukemia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Despite good initial response, some patients with core binding factor and/or NPM1-mutated AML eventually relapse. Some of these patients can be identified earlier on, before overt cytological relapse, when followed for minimal residual disease. The outcome of patients treated when molecular relapse is confirmed, before overt cytological relapse, is not well known. This multi-center retrospective will therefore study the outcome of these patients and try to specify the role of allogeneic stem cell transplantation in this setting.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Molecular relapse after first-line intensive therapy in patients with CBF or NPM1-mutated acute myeloid leukemia - a FILO study.
Orvain C, Bertoli S, Peterlin P, Desbrosses Y, et al · · 2024 · cited 14× · PMID 39020060 · DOI 10.1038/s41375-024-02335-2
<i>NPM1</i>-Mutated AML: Deciphering the Molecular and Clinical Puzzle in the Era of Novel Treatment Strategies.
Diamantidis MD, Vlachou MS, Katsikavela A, Kalomoiri S, et al · · 2025 · PMID 40647396 · DOI 10.3390/cancers17132095

Verify or expand the search:

Other trials of No intervention

Trials testing the same drug.

NCT06643052 — Cahnge in Management of Suspected Early Onset Neonetal Sepsis After Assimilation of Early Onset Sepsis Calculator · not yet recruiting
NCT07540611 — Gonadotropin Therapy in Idiopathic Hypogonadal Non-Obstructive · NA · not yet recruiting
NCT07291778 — Doppler Evaluation for Congestive Acute Kidney Injury in Critical Illness · NA · not yet recruiting
NCT07490431 — An Observational Study to Learn More About How Elinzanetant is Used and How Well it Works for Women With Menopause Sympt · not yet recruiting
NCT07515365 — Colitis Patterns in Patients With Lower GI Symptoms · not yet recruiting

Other recruiting trials for Acute Myeloid Leukemia

Currently open trials in the same condition.

NCT07020533 — A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Pa · Phase 1 · recruiting
NCT06782542 — Olutasidenib, Venetoclax, and Azacitidine in IDH1 Mutated Newly Diagnosed Acute Myeloid Leukemia Patients Eligible for I · Phase 2 · recruiting
NCT07177079 — High-dose Ascorbate (HDA) in Combination With Standard of Care Azacitidine and Venetoclax in Acute Myeloid Leukemia (AML · Phase 1 · recruiting
NCT07384715 — First-in-human (FIH) Trial of GEN3018 in Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) or Higher-risk Myelod · Phase 1 · recruiting
NCT07107126 — Safety and Proof-of-Concept Study of RPT1G in Adults With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndromes · Phase 1 · recruiting

Other University Hospital, Angers trials

Trials by the same sponsor.

NCT05791994 — EVASION: Effect of VisuAl Stimulation on attentION · NA · recruiting
NCT07470294 — Effectiveness of Different Surgical Techniques for Curative Treatment of Pilonidal Sinus Disease in the Pediatric Popula · not yet recruiting
NCT07409597 — Autobiographical Memory, Future Thought, and Eye Movements in Huntington's Disease · NA · not yet recruiting
NCT07468565 — Surgical Approach for the Treatment of Hirschsprung Disease Using the Swenson Technique (SMILES) · not yet recruiting
NCT07452952 — Relationship Between the Level of Positive End-expiratory Pressure and Venous Congestion During Acute Respiratory Distre · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04931992 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University Hospital, Angers
Last refreshed: 18 June 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04931992.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing